Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Rating) has been assigned an average recommendation of "Buy" from the eleven brokerages that are presently covering the stock, Marketbeat.com reports. Eight analysts have rated the stock with a buy rating. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $46.56.
Several research firms recently weighed in on ZNTL. Oppenheimer cut their price target on shares of Zentalis Pharmaceuticals from $80.00 to $50.00 and set an "outperform" rating on the stock in a report on Thursday, November 10th. Wedbush cut their price target on shares of Zentalis Pharmaceuticals from $51.00 to $32.00 and set an "outperform" rating on the stock in a report on Monday, November 14th. Morgan Stanley cut their price target on shares of Zentalis Pharmaceuticals from $60.00 to $55.00 and set an "overweight" rating on the stock in a report on Friday, November 11th. SVB Leerink cut their price target on shares of Zentalis Pharmaceuticals from $42.00 to $27.00 and set an "outperform" rating on the stock in a report on Thursday, November 10th. Finally, Guggenheim cut their price target on shares of Zentalis Pharmaceuticals from $55.00 to $28.00 and set a "buy" rating on the stock in a report on Friday, November 11th.
Get
Zentalis Pharmaceuticals alerts:
Insider Buying and Selling at Zentalis Pharmaceuticals
In other Zentalis Pharmaceuticals news, President Cam Gallagher sold 12,500 shares of the business's stock in a transaction dated Monday, November 7th. The shares were sold at an average price of $23.67, for a total value of $295,875.00. Following the transaction, the president now directly owns 396,885 shares in the company, valued at $9,394,267.95. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders have sold a total of 50,000 shares of company stock worth $1,153,375 over the last three months. 19.90% of the stock is currently owned by insiders.
Institutional Trading of Zentalis Pharmaceuticals
Several hedge funds and other institutional investors have recently modified their holdings of the business. Bank of New York Mellon Corp raised its position in shares of Zentalis Pharmaceuticals by 29.1% in the third quarter. Bank of New York Mellon Corp now owns 152,808 shares of the company's stock valued at $3,310,000 after purchasing an additional 34,429 shares during the period. Teachers Retirement System of The State of Kentucky bought a new stake in shares of Zentalis Pharmaceuticals in the third quarter valued at approximately $647,000. California State Teachers Retirement System raised its position in shares of Zentalis Pharmaceuticals by 4.5% in the third quarter. California State Teachers Retirement System now owns 57,749 shares of the company's stock valued at $1,251,000 after purchasing an additional 2,479 shares during the period. Sandia Investment Management LP bought a new stake in shares of Zentalis Pharmaceuticals in the third quarter valued at approximately $108,000. Finally, BNP Paribas Arbitrage SNC bought a new stake in shares of Zentalis Pharmaceuticals in the third quarter valued at approximately $1,658,000.
Zentalis Pharmaceuticals Price Performance
NASDAQ:ZNTL opened at $18.28 on Friday. The firm has a 50-day moving average of $21.55 and a 200-day moving average of $24.69. The company has a market cap of $1.04 billion, a PE ratio of -3.87 and a beta of 1.80. Zentalis Pharmaceuticals has a one year low of $17.33 and a one year high of $85.95.
Zentalis Pharmaceuticals Company Profile
(Get Rating)
Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker.
Featured Articles
- Get a free copy of the StockNews.com research report on Zentalis Pharmaceuticals (ZNTL)
- MarketBeat: Week in Review 12/19 – 12/23
- These Steelmakers Deserve A Place On Your 2023 Watch List
- Inflation Cools, Where Does The S&P 500 Go Now
- Cintas Beats Inflation With Operating Leverage
- Your Decision to Buy Palantir May Simply Be a Matter of Time
Receive News & Ratings for Zentalis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentalis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
